Compare AU
Compare CURE vs. EDOC
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Digital Health and Telemedicine ETF (EDOC). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | EDOC | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 7 |
Median incremental investment | $619.50 | $705.01 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $192.66 |
Average age group | > 35 | > 35 |
Key Summary
CURE | EDOC | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | EDOC.AX was created on 2022-03-30 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. The investment objective of the BetaShares Digital Health and Telemedicine ETF is to provide an investment return that aims to track the performance of the NASDAQ CTA Global Digital Health Index (the Index), before taking into account fees and expenses. |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | INSULET CORP (8.47 %) BOSTON SCIENTIFIC CORP (8.24 %) ABBOTT LABORATORIES (7.76 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Health Care (75.06 %) Other (24.70 %) Consumer Staples (14.33 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (77.51 %) China (13.32 %) Japan (4.67 %) |
Management fee | 0.45 % | 0.67 % |
Key Summary
CURE | EDOC | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | Nasdaq CTA Global Digital Health Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.67 % |
Price | $49.94 | $10.14 |
Size | $38.065 million | $1.618 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | - % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 29/03/2022 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | EDOC | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 7 |
Median incremental investment | $619.50 | $705.01 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $192.66 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | EDOC | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | EDOC |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |